Circulating MicroRNA-423-3p Improves the Prediction of Coronary Artery Disease in a General Population　― Six-Year Follow-up Results From the China-Cardiovascular Disease Study ―

Abstract

significance for the overall reduction of CVD mortality. 7 This calls for biomarkers of CAD in clinical practice.MicroRNAs (miRNAs) are small non-coding molecules that play an important role in development of atherosclerosis and their expression altered during CAD events. 8,9 In 2008, Lawrie et al first reported the presence of miRNAs in biological fluids, which triggered an upsurge in research C ardiovascular disease (CVD) is one of the most important public health issues in the world. 1 Data from World Health Organization indicates that approximately 17.5 million people died from CVDs in 2012 (7.4 million caused by coronary artery disease (CAD)), which accounts for 31% of all global deaths. 2 Among CVDs, CAD remains the leading cause of mortality worldwide. [3][4][5] In Asia, there is an increasing CAD burden because of rising prevalence of sedentary lifestyle and changes in food consumption. 6 Early prevention of CAD is of clinical Editorial p 1062

Circulating MicroRNAs as Novel Biomarkers in Risk Assessment and Prognosis of Coronary Artery Disease

“…The same year, Wang et al reported a negative correlation of miR-423-3p with the risk of CAD events, showing added predictive ability to TRFs. [ 43 ] To identify the most specific miRNAs associated with CAD, they implemented a multistep design. They initially performed a screening by miRNA sequencing on pooled samples of serum or peripheral blood monocytes from 10 CAD patients and 10 healthy controls, as well as hypoxia-treated vascular endothelial cells (ECs).…”

“…Indeed, although circulating miRNAs have been shown to add predictive capacity to TRFs-based risk scores in several primary prevention studies, the poor reproducibility of the results and the different clinical endpoints considered limit their prospective use in clinical practice. [ 26 , 29 , 31 , 32 , 43 ]…”

“…Indeed, although circulating miRNAs have been shown to add predictive capacity to TRFs-based risk scores in several primary prevention studies, the poor reproducibility of the results and the different clinical endpoints considered limit their prospective use in clinical practice. 26,29,31,32,43 Furthermore, single miRNAs are rarely disease-specific, whereas combining miRNAs in panels increases specificity and slightly/moderately increases the predictive power of conventional scores. In contrast, secondary prevention studies have also provided conflicting results.…”

Role of Selected miRNAs as Diagnostic and Prognostic Biomarkers in Cardiovascular Diseases, Including Coronary Artery Disease, Myocardial Infarction and Atherosclerosis

“…MiR-423-5p is localized in chromosome 17q11.2 in the intron of the nuclear speckle splicing regulatory protein 1 gene [84]. It has been reported that there is a difference in the microR-423-5p trans-coronary gradients between patients with stable systolic heart failure and healthy controls, and it is suggested that miR-423-5p originates from heart tissues [85,86]. It has been shown that the microR-423-5p serum levels were significantly higher in patients with unstable angina pectoris than patients with stable angina pectoris and aortic stenosis [87,88].…”

Exosome miR-501-3p Elevation Contributes to Progression of Vascular Stiffness

“…5 For example, exosomemediated transfer of miRNAs has been shown to regulate various physiological processes in the context of neurological and cardiovascular diseases. 6,7 Although an increasing number of studies has highlighted the impact of miRNAs on the development of arterial stiffness, no treatment or biomarker has yet been established in clinical practice. 8 Thus, the search for clinically optimal miRNAbased treatments and biomarkers for vascular diseases is…”